178 related articles for article (PubMed ID: 37122207)
1. Patient-specific induced pluripotent stem cell properties implicate Ca
Zhou Y; Huang W; Liu L; Li A; Jiang C; Zhou R; Wang J; Tan X; Huang CL; Zhang Y
Philos Trans R Soc Lond B Biol Sci; 2023 Jun; 378(1879):20220175. PubMed ID: 37122207
[TBL] [Abstract][Full Text] [Related]
2. Generation of induced pluripotent stem cells (iPSCs) from an infant with catecholaminergic polymorphic ventricular tachycardia carrying the double heterozygous mutations A1855D in RyR2 and Q1362H in SCN10A.
Zhang Y; Li A; Huang CL; Wang G; Wang D
Stem Cell Res; 2019 Aug; 39():101509. PubMed ID: 31382203
[TBL] [Abstract][Full Text] [Related]
3. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells.
Fatima A; Xu G; Shao K; Papadopoulos S; Lehmann M; Arnáiz-Cot JJ; Rosa AO; Nguemo F; Matzkies M; Dittmann S; Stone SL; Linke M; Zechner U; Beyer V; Hennies HC; Rosenkranz S; Klauke B; Parwani AS; Haverkamp W; Pfitzer G; Farr M; Cleemann L; Morad M; Milting H; Hescheler J; Saric T
Cell Physiol Biochem; 2011; 28(4):579-92. PubMed ID: 22178870
[TBL] [Abstract][Full Text] [Related]
4. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
[TBL] [Abstract][Full Text] [Related]
5. Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R.
Zhang XH; Wei H; Xia Y; Morad M
Heart Rhythm; 2021 Feb; 18(2):250-260. PubMed ID: 32931925
[TBL] [Abstract][Full Text] [Related]
6. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
[TBL] [Abstract][Full Text] [Related]
7. A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes.
El-Battrawy I; Albers S; Cyganek L; Zhao Z; Lan H; Li X; Xu Q; Kleinsorge M; Huang M; Liao Z; Zhong R; Rudic B; Müller J; Dinkel H; Lang S; Diecke S; Zimmermann WH; Utikal J; Wieland T; Borggrefe M; Zhou X; Akin I
Europace; 2019 Sep; 21(9):1410-1421. PubMed ID: 31106349
[TBL] [Abstract][Full Text] [Related]
8. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.
Zhang XH; Haviland S; Wei H; Sarić T; Fatima A; Hescheler J; Cleemann L; Morad M
Cell Calcium; 2013 Aug; 54(2):57-70. PubMed ID: 23684427
[TBL] [Abstract][Full Text] [Related]
9. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
[TBL] [Abstract][Full Text] [Related]
10. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
[TBL] [Abstract][Full Text] [Related]
11. Modeling polymorphic ventricular tachycardia at rest using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Sleiman Y; Souidi M; Kumar R; Yang E; Jaffré F; Zhou T; Bernardin A; Reiken S; Cazorla O; Kajava AV; Moreau A; Pasquié JL; Marks AR; Lerman BB; Chen S; Cheung JW; Evans T; Lacampagne A; Meli AC
EBioMedicine; 2020 Oct; 60():103024. PubMed ID: 32980690
[TBL] [Abstract][Full Text] [Related]
12. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
[TBL] [Abstract][Full Text] [Related]
13. Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential.
Stutzman MJ; Kim CSJ; Tester DJ; Hamrick SK; Dotzler SM; Giudicessi JR; Miotto MC; Gc JB; Frank J; Marks AR; Ackerman MJ
Stem Cell Reports; 2022 Sep; 17(9):2023-2036. PubMed ID: 35931078
[TBL] [Abstract][Full Text] [Related]
14. Contribution of the neuronal sodium channel Na
Bengel P; Ahmad S; Tirilomis P; Trum M; Dybkova N; Wagner S; Maier LS; Hasenfuß G; Sossalla S
J Mol Cell Cardiol; 2020 Jul; 144():35-46. PubMed ID: 32418916
[TBL] [Abstract][Full Text] [Related]
15. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the mechanism by which a nonsense variant in RYR2 leads to disordered calcium handling.
Hopton C; Tijsen AJ; Maizels L; Arbel G; Gepstein A; Bates N; Brown B; Huber I; Kimber SJ; Newman WG; Venetucci L; Gepstein L
Physiol Rep; 2022 Apr; 10(8):e15265. PubMed ID: 35439358
[TBL] [Abstract][Full Text] [Related]
17. Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia.
Fernández-Velasco M; Rueda A; Rizzi N; Benitah JP; Colombi B; Napolitano C; Priori SG; Richard S; Gómez AM
Circ Res; 2009 Jan; 104(2):201-9, 12p following 209. PubMed ID: 19096022
[TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.
Penttinen K; Swan H; Vanninen S; Paavola J; Lahtinen AM; Kontula K; Aalto-Setälä K
PLoS One; 2015; 10(5):e0125366. PubMed ID: 25955245
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of the calcium release channel deficiency syndrome.
Tester DJ; Kim CSJ; Hamrick SK; Ye D; O'Hare BJ; Bombei HM; Fitzgerald KK; Haglund-Turnquist CM; Atkins DL; Nunez LAO; Law I; Temple J; Ackerman MJ
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32663189
[TBL] [Abstract][Full Text] [Related]
20. Non-ventricular, Clinical, and Functional Features of the RyR2(R420Q) Mutation Causing Catecholaminergic Polymorphic Ventricular Tachycardia.
Domingo D; Neco P; Fernández-Pons E; Zissimopoulos S; Molina P; Olagüe J; Suárez-Mier MP; Lai FA; Gómez AM; Zorio E
Rev Esp Cardiol (Engl Ed); 2015 May; 68(5):398-407. PubMed ID: 25440180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
